» Articles » PMID: 28587313

MicroRNA-223-3p Regulates Ovarian Cancer Cell Proliferation and Invasion by Targeting SOX11 Expression

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2017 Jun 8
PMID 28587313
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNAs (miRNAs) often display different expression in many cancers and other diseases in current research studies. miR-223 expression is upregulated in rheumatoid arthritis. Also, miR-223 expression has been demonstrated to be highly expressed in pancreatic cancer and gastric cancer in comparison with normal tissue. However, whether miR-223 displays different expression in ovarian cancer and what its underlying functions are in ovarian cancer have remained unclear. In this study, we demonstrated that miR-223-3p was upregulated in ovarian cancer tissue. Next, we explored the functional role of miR-223-3p in ovarian cancer using SKOV3 and OVCAR3 cell lines. Our results suggested that miR-223-3p mimic promoted ovarian cancer cell proliferation, migration, and invasion in vitro. However, miR-223-3p inhibitor displayed the opposite effects. In addition, we demonstrated that miR-223-3p mimic promoted tumor growth in vivo. Furthermore, we found SOX11 (sex determining region Y-box 11) was inversely expressed with miR-223-3p in ovarian cancer (OC) cell lines and tissue specimens. miR-223-3p mimic decreased SOX11 expression. Overexpressing SOX11 inhibited ovarian cancer cell proliferation and invasion, which indicated that miR-223-3p regulated OC cell proliferation and invasion through targeting SOX11 expression. In conclusion, the findings of the present study demonstrated that miR-223-3p could be a potential therapeutic for ovarian cancer.

Citing Articles

Exosomal ncRNAs in reproductive cancers†.

Kowalczyk A, Wrzecinska M, Galeska E, Czerniawska-Piatkowska E, Camina M, Araujo J Biol Reprod. 2024; 112(2):225-244.

PMID: 39561105 PMC: 11833474. DOI: 10.1093/biolre/ioae170.


as a potential prognostic biomarker in hepatocellular carcinoma linked to immune infiltration and ferroptosis.

Chen H, Ao Q, Wang Y, Qian Y, Cheng Q, Zhang W Chin J Cancer Res. 2024; 36(4):378-397.

PMID: 39246708 PMC: 11377886. DOI: 10.21147/j.issn.1000-9604.2024.04.03.


MiR-223-3p in Cancer Development and Cancer Drug Resistance: Same Coin, Different Faces.

Barbagallo D, Ponti D, Bassani B, Bruno A, Pulze L, Akkihal S Int J Mol Sci. 2024; 25(15).

PMID: 39125761 PMC: 11311375. DOI: 10.3390/ijms25158191.


Ovarian Cancer and the Microbiome: Connecting the Dots for Early Diagnosis and Therapeutic Innovations-A Review.

Choi S, Choi J Medicina (Kaunas). 2024; 60(3).

PMID: 38541242 PMC: 10972291. DOI: 10.3390/medicina60030516.


Diagnostic value of plasma-derived exosomal miR-223 for epithelial ovarian cancer.

Yang L, Yang Z, Liu Z, Qi N, Tao L BMC Womens Health. 2024; 24(1):150.

PMID: 38431592 PMC: 10908149. DOI: 10.1186/s12905-024-02976-6.


References
1.
Wang H, Peng W, Ouyang X, Li W, Dai Y . Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. Transl Res. 2012; 160(3):198-206. DOI: 10.1016/j.trsl.2012.04.002. View

2.
Wei Y, Yang J, Yi L, Wang Y, Dong Z, Liu Z . MiR-223-3p targeting SEPT6 promotes the biological behavior of prostate cancer. Sci Rep. 2014; 4:7546. PMC: 4269886. DOI: 10.1038/srep07546. View

3.
He L, Hannon G . MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5(7):522-31. DOI: 10.1038/nrg1379. View

4.
Bloomston M, Frankel W, Petrocca F, Volinia S, Alder H, Hagan J . MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007; 297(17):1901-8. DOI: 10.1001/jama.297.17.1901. View

5.
Osada H, Takahashi T . MicroRNAs in biological processes and carcinogenesis. Carcinogenesis. 2006; 28(1):2-12. DOI: 10.1093/carcin/bgl185. View